Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Radiotherapy 214Cisplatin 180Cyclophosphamide 169Doxorubicin 138Vincristine 127Paclitaxel 125Filgrastim 121Etoposide 104Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NETWORK × GEN-1 × Clear all
NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 1 Completed
16 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01118052 2018-01-11

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
22 enrolled 8 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡